Over the last fifteen years, numerous studies have sought to decipher the role of lipoprotein-associated phospholipase A (Lp-PLA) in vascular inflammation-related diseases, notably atherosclerosis. Despite the disappointing results of clinical trials using the Lp-PLA inhibitor darapladib, new pathophysiological, epidemiological and genetic data have enabled the development of new inhibitors. Recent studies also show that Lp-PLA is involved in vascular inflammation-related diseases other than atherosclerosis (ischemic stroke, Alzheimer's disease and vascular dementia, diabetes, cancers…), and inhibition of Lp-PLA could have beneficial therapeutic in these diseases. This review aims to present new data on Lp-PLA and to evaluate its current interest as a biomarker but also as a therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharma.2024.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contribution of individual phospholipase A enzymes to the cleavage of oxidized phospholipids in human blood plasma.
J Lipid Res
January 2025
Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria; Field of Excellence BioHealth - University of Graz, Graz, Austria. Electronic address:
Phospholipids containing oxidized esterified PUFA residues (OxPLs) are increasingly recognized for multiple biological activities and causative involvement in disease pathogenesis. Pharmacokinetics of these compounds in blood plasma is essentially not studied. Human plasma contains both genuine phospholipases A (PAF-AH (also called Lp-PLA) and sPLA) and multifunctional enzymes capable of removing sn-2 residues in native and oxidized PLs (LCAT, PRDX6).
View Article and Find Full Text PDFClinical observation of Danlou tablets combined with aspirin for phlegm and blood stasis syndrome in coronary heart disease: impact on related serum factors.
Am J Transl Res
November 2024
Emergency Department, Dongying People's Hospital Dongying 257000, Shandong, China.
Objectives: To investigate the effect of Danlou tablets combined with aspirin for treating phlegm and blood stasis syndrome in coronary heart disease (CHD).
Methods: This study is a retrospective study, a total of 120 patients with phlegm and blood stasis syndrome with CHD were randomly assigned to either a control group (aspirin, 100 mg, once daily) or an observation group (Danlou tablets, 1.5 g, three times daily; aspirin, 100 mg, once daily) at a 1:1 ratio.
Oxidative stress indexes as biomarkers of the severity in COVID-19 patients.
Int J Med Sci
December 2024
Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
: SARS-CoV-2 causes a global pandemic, with severe and critically ill COVID-19 patients often experiencing poor prognoses. Severe infection with SARS-CoV-2 is associated with oxidative stress (OS) and inflammation. Detecting markers of macromolecular damage caused by OS may provide valuable insights into disease progression.
View Article and Find Full Text PDFLipoprotein-associated phospholipase A activity levels is associated with artery to artery embolism in symptomatic intracranial atherosclerotic disease.
J Stroke Cerebrovasc Dis
November 2024
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China; National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100071, China; Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing 100071, China; Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China.
Article Synopsis
- Lipoprotein-associated phospholipase A activity (Lp-PLA-A) is crucial for understanding inflammation and risk of stroke, especially in patients with symptomatic intracranial atherosclerotic disease (sICAD).
- A study involving 1,908 patients analyzed the relationship between Lp-PLA-A levels and the incidence of artery-to-artery embolism (AAE), revealing higher rates of cortical infarction as Lp-PLA-A levels increased.
- Results showed that patients in higher Lp-PLA-A quartiles had significantly higher odds of AAE and cortical infarction, with odds ratios ranging from 1.33 to 1.48 compared to those in the lowest quartile.
[Lipoprotein-associated phospholipase A (Lp-PLA): Relevant biomarker and therapeutic target?].
Ann Pharm Fr
January 2025
Service de biochimie métabolique, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris, France; Inserm, CNRS, UFR de pharmacie, UTCBS, université Paris Cité, Paris, France. Electronic address:
Over the last fifteen years, numerous studies have sought to decipher the role of lipoprotein-associated phospholipase A (Lp-PLA) in vascular inflammation-related diseases, notably atherosclerosis. Despite the disappointing results of clinical trials using the Lp-PLA inhibitor darapladib, new pathophysiological, epidemiological and genetic data have enabled the development of new inhibitors. Recent studies also show that Lp-PLA is involved in vascular inflammation-related diseases other than atherosclerosis (ischemic stroke, Alzheimer's disease and vascular dementia, diabetes, cancers…), and inhibition of Lp-PLA could have beneficial therapeutic in these diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!